- Risankizumab is associated with superior efficacy compared with adalimumab for patients with moderate to severe psoriasis, according to a meta-analysis.
Why this matters
- The meta-analysis supports results of a head-to-head trial (not included) demonstrating risankizumab superiority.
- Risankizumab was associated with superior clinical efficacy compared with adalimumab after 16 weeks:
- Estimated effect difference, 8.57% (95% CI, 5.59%-11.8%) for ≥50% improvement in the Psoriasis Area and Severity Index (PASI50).
- Estimated effect difference, 15.2% (95% CI, 10.1%-20.4%) for PASI75.
- Estimated effect difference, 23.7% (95% CI, 15.7%-31.2%) for PASI90.
- Estimated effect difference, 20.8% (95% CI, 13.0%-28.7%) for PASI100.
- Estimated effect difference, 20.1% (95% CI, 13.7%-26.1%) for a static Physician Global Assessment (sPGA) score of 0/1.
- The effect differences were similar to those observed in the IMMvent head-to-head trial (13.5% for PASI50, 19.0% for PASI75, 25.1% for PASI90, 16.8% for PASI100, and 23.5% for sPGA 0/1).
- 8 randomised controlled trials (3 for risankizumab and 5 for adalimumab) were included in the meta-analysis.
- Funding: AbbVie.
- No analysis of long-term efficacy.
- No safety comparison.